Massive but selective cytokine dysregulation in the colon of IL-10-/- mice revealed by multiplex analysis

International Immunology

Volumn 20, Issue 1, 2008, Pages 141-154

  Montufar Solis, Dina ^a   Schaefer, Jeremy ^a   Hicks, M John ^b   Klein, John R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cell activation; Chemokine; Cytokine; Mucosa; Rodent

Indexed keywords

CXCL1 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; COLON; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; ENTERITIS; ENTEROCOLITIS; FEMALE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATION; LEUKOCYTE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM;

ANIMALS; COLITIS; COLON; CYTOKINES; EPITHELIAL CELLS; FEMALE; INTERLEUKIN-10; LEUKOCYTES; MALE; MICE; MICE, INBRED BALB C;

EID: 37549047983     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxm126     Document Type: Article

References (51)

1. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. and Muller, W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263.
2. Mombaerts, P., Mizoguchi, E., Grusby, M, J., Glimcher, L. H., Bhan, A. K. and Tonegawa, S. 1993. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75:274.
3. Moore, K. W., de Waal Malefyt, R., Coffman, R. L. and O'Garra, A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev Immunol. 19:683.
4. Sellon, R. K., Tonkonogy, S., Schultz, M. et al. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66:5224.
5. Strober, W., Fuss, I. J. and Blumberg, R. S. 2002. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20:495.
6. Berg, D. J., Davidson, N., Kuhn, R. et al. 1996. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J. Clin. Investig. 98:1010.
7. Specht, S., Arriens, S. and Hoerauf, A. 2006. Induction of chronic colitis in IL-10 deficient mice requires IL-4. Microbes Infect. 8:694.
8. Yen, D., Cheung, J., Scheerens, H. et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Investig. 116:1310.
9. Shiraki, M., Aihara, H., Kinouchi, Y. et al. 2004. IL-12 p40 prevents the development of chronic enterocolitis in IL-10-deficient mice. Lab. Investig. 84:1491.
10. Davidson, N. J., Leach, M. W., Fort, M. M. et al. 1996. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. 184:241.
11. Kinugasa, T., Sakaguchi, T., Gu, X. and Reinecker, H. C. 2000. Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology 118:1001.
12. Colgan, S. P., Resnick, M. B., Parkos, C. A. et al. 1994. IL-4 directly modulates function of a model human intestinal epithelium. J. Immunol. 153:2122.
13. Schmitz, H., Fromm, M., Bentzel, C. J. et al. 1999. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J. Cell Sci. 112:137.
14. Youakim, A. and Ahdieh, M. 1999, Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. Am. J. Physiol. 276:G1279.
15. Ozaki, H., Ishii, K., Horiuchi, H. et al. 1999. Cutting edge: combined treatment of TNF-alpha and IFN-gamma causes redistribution of junctional adhesion molecule in human endothelial cells. J. Immunol. 163:553.
16. Lui, W. Y., Lee, W. M. and Cheng, C. Y. 2001. Transforming growth factor-beta3 perturbs the inter-Sertoli tight junction permeability barrier in vitro possibly mediated via its effects on occludin, zonula occludens-1, and claudin-11. Endocrinology 142: 1865.
17. Nusrat, A., Turner, J. R. and Madara, J. L. 2000. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells. Am. J. Physiol. Gastrointest. Liver Physiol. 279:G851.
18. Stevens, A. C., Matthews, J., Andres, P. et al. 1997. Interleukin-15 signals T84 colonic epithelial cells in the absence of the interleukin-2 receptor beta-chain. Am. J. Physiol. 272:G1201.
19. Bruewer, M., Samarin, S. and Nusrat, A. 2006. Inflammatory bowel disease and the apical junctional complex. Ann. N. Y. Acad. Sci. 1072:242.
20. Neurath, M. F., Fuss, I., Kelsall, B. L., Stuber, E. and Strober, W. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:1281.
21. Montufar-Solis, D. and Klein, J. R. 2006. An improved method for isolating intraepithelial lymphocytes (IELs) from the murine small intestine with consistently high purity. J. Immunol. Methods 308:251.
22. Livak, K. J. and Schmittgen, T. D. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25:402.
23. Ishii, K., Kanai, T., Totsuka, T. et al. 2004. Hyperexpression of inducible costimulator on lamina propria mononuclear cells in rat dextran sulfate sodium colitis. J. Gastroenterol. Hepatol. 19:174.
24. Totsuka, T., Kanai, T, Iiyama, R. et al. 2003. Ameliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis. Gastroenterology 124:410.
25. Sato, T., Kanai, T., Watanabe, M. et al. 2004. Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease. Gastroenterology 126:829.
26. Park, H., Li, Z., Yang, X. O. et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133.
27. Infante-Duarte, C., Horton, H. F., Byrne, M. C. and Kamradt, T. 2000. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165:6107.
28. Harrington, L. E., Hatton, R. D., Mangan, P. R. et al. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123.
29. Hue, S., Ahern, P., Buonocore, S. et al. 2006. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203:2473.
30. Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. and Gurney, A. L. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910.
31. Chackerian, A. A., Chen, S. J., Brodie, S. J. et al. 2006. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect. Immun. 74:6092.
32. Langrish, C. L., Chen, Y., Blumenschein, W. M. et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233.
33. Zhou, L. 2007. Ivanov, I. I., Spolski, R. et al. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967.
34. Korzenik, J. R. and Dieckgraefe, B. K. 2000. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig. Dis. Sci. 45:1121.
35. Dieckgraefe, B. K. and Korzenik, J. R. 2002. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360:1478.
36. Korzenik, J. R. and Dieckgraefe, B. K. 2005. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment. Pharmacol. Ther. 21:391.
37. Heller, F, Florian, P., Bojarski, C. et al. 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129:550.
38. de Waal Malefyt, R., Figdor, C. G., Huijbens, R. et al. 1993. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-garnma or IL-10. J. Immunol. 151:6370.
39. Hart, P. H., Ahern, M. J., Smith, M. D. and Finlay-Jones, J. J. 1995. Regulatory effects of IL-13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Clin. Exp. Immunol. 99:331.
40. Kelly, A. M., Golden-Mason, L., Traynor, O. et al. 006. Changes in hepatic immunoregulatory cytokines in patients with metastatic colorectal carcinoma: Implications for hepatic anti-tumour immunity. Cytokine 35:171.
41. Opal, S. M. and DePalo, V A. 2000. Anti-inflammatory cytokines. Chest 117:1162.
42. Lee, C. G., Homer, R. J., Zhu, Z. et al. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J. Exp. Med. 194:809.
43. Kitani, A., Fuss, I., Nakamura, K., Kumaki, F., Usui, T. and Strober, W. 2003. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J. Exp. Med. 198:1179.
44. Donaldson, D. D., Whitters, M. J., Fitz, L. J. et al. 1998. The murine IL-13 receptor alpha 2: Molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J. Immunol. 161:2317.
45. Wynn, T A., Morawetz, R., Scharton-Kersten, T. et al. 1997. Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1- and T helper cell 2-type cytokine responses in vivo. J. Immunol. 159:5014.
46. Rigby, W. F. 2007. Drug insight: Different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat. Clin. Pract Rheumatol. 3:227.
47. Perdow-Hickman, S. and Salgame, P. 2000. Rescue of human T cells by interieukin-9 (IL-9) from IL-2 deprivation-induced apoptosis: correlation with alpha subunit expression of the IL-9 receptor. J. Interferon Cytokine Res. 20:603.
48. Gessner, A., Blum, H. and Rollinghoff, M. 1993. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 189:419.
49. Dugas, B., Renauld, J. C., Pene, J. et al. 1993. Interleukin-9 potentiates the interieukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur. J. Immunol. 23:1687.
50. Dong, Q., Louahed, J., Vink, A. et al. 1999. IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Eur. J. Immunol. 29:2130.
51. Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C. and Horak, I. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253.